Trial · NCT01867502
Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes
NCT01867502, Phase 4, Unknown, Hospital de Clinicas de Porto Alegre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes. Trials, record NCT01867502. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01867502
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes
- NCT number
- NCT01867502
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Hospital de Clinicas de Porto Alegre
- Conditions
- Diabetes Mellitus, Type 2, Hypoglycemic Agents, Diabetic Blood Glucose Monitoring, Exercise
- Interventions
- MET + Vildagliptin Group, MET + Glibenclamide Group
- First posted
- 2013-06-04
- Last updated
- 2014-05-06
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Glycemic variability | Baseline and 12 weeks | Continuous glucose monitoring system (CGMS) during 48 hours (24h before and 24 after the submaximal exercise test). |
| Secondary | Change in Hemodynamic response to exercise: Cardiac output (Q), Stroke Volume (SV) and blood pressure (BP) | Each 2 minutes during exercise and until 60 min post in baseline and 12 weeks | Cardiac output (Q) and the Stroke Volume (SV)and blood pressure (BP) will be measured before the sub-maximal tests, 10% below the second threshold and every 2 minutes of recovery. |
| Other | Change in Flow Mediated Dilatation (FMD) | Baseline and 12 weeks | This analysis will be performed by a high-resolution ultrasound of the brachial artery (doppler vascular), which characterizes the Flow Mediated Dilatation (FMD), which is expressed by changes in basal diameter in response to the increased flow and Nitroglycerin (NTG), which will be applied in a single dose (0.4 mg) as a sublingual spray. |
| Other | Change in Blood pressure variability | Baseline and 12 weeks | Blood Pressure Monitoring Sensor (BPMS)which will be programmed to automatically measuring the blood pressure every 15 minutes during the day (06:00 to 22:00 h), and every 20 minutes during the night (22:00 to 6:00 h. |
| Other | Change in Plasma glucagon concentration on exercise | -1h, 0, 15min, 30 min (end), 60min post exercise in baseline and 12 weeks | EDTA Vacutainer tubes of 10 ml will be used to perform the blood tests and they will be stored at -20º to send them to the Molecular and Proteins Analysis Unit after buying specific kit. |
| Other | Change in Oxidative stress (F2 isoprostane 8-iso prostaglandin F2α); | Baseline and 12 weeks. | The 24-hour urinary samples will be collected at visit 1 and 4 to evaluate the oxidative stress. Free 8-iso PGF2α that is most frequently measured F2 isoprostane in body fluids. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25366037 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01867502
GET https://conductscience.org/api/trials/v1/NCT01867502/registered